Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 2 - Any |
| Updated: | 1/17/2019 |
| Start Date: | April 15, 2014 |
| End Date: | December 1, 2019 |
| Contact: | Pamela D Graham |
| Email: | edmondsp@mail.nih.gov |
| Phone: | (301) 435-7173 |
This study is a longitudinal and cross-sectional evaluation of patients with Chronic
Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation
(HCT) for their disease under a variety of protocols used by participating institutions
compared to a control non-HCT group receiving standard care. Investigators at multiple
centers caring for patients with CGD in North America and 3 centers in Europe will
participate. Patients with CGD will have been treated according to institutional practice and
protocols. Investigators will enroll these patients as subjects in this protocol. This study
will investigate which patients benefit most from HCT, and what types of transplants are
optimal for patients with CGD, in the context of overall outcomes in CGD patients with and
without transplant.
Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation
(HCT) for their disease under a variety of protocols used by participating institutions
compared to a control non-HCT group receiving standard care. Investigators at multiple
centers caring for patients with CGD in North America and 3 centers in Europe will
participate. Patients with CGD will have been treated according to institutional practice and
protocols. Investigators will enroll these patients as subjects in this protocol. This study
will investigate which patients benefit most from HCT, and what types of transplants are
optimal for patients with CGD, in the context of overall outcomes in CGD patients with and
without transplant.
This study is a longitudinal and cross-sectional evaluation of patients with Chronic
Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation
(HCT) for their disease under a variety of protocols used by participating institutions
compared to a control non-HCT group receiving standard care. Investigators at multiple
centers caring for patients with CGD in North America and 3 centers in Europe will
participate. Patients with CGD will have been treated according to institutional practice and
protocols. Investigators will enroll these patients as subjects in this protocol. This study
will investigate which patients benefit most from HCT, and what types of transplants are
optimal for patients with CGD, in the context of overall outcomes in CGD patients with and
without transplant.
Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation
(HCT) for their disease under a variety of protocols used by participating institutions
compared to a control non-HCT group receiving standard care. Investigators at multiple
centers caring for patients with CGD in North America and 3 centers in Europe will
participate. Patients with CGD will have been treated according to institutional practice and
protocols. Investigators will enroll these patients as subjects in this protocol. This study
will investigate which patients benefit most from HCT, and what types of transplants are
optimal for patients with CGD, in the context of overall outcomes in CGD patients with and
without transplant.
- Both HCT and non-HCT subjects must be over the age of 2 and actively enrolled and
receiving treatment under a CGD protocol at NIAID.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 800-411-1222
Click here to add this to my saved trials
